Myasthenia gravis and specific immunotherapy: monoclonal antibodies

Cai, Xiao-Jun1,2; Li, Zai-Wang3,4; Xi, Jian-Ying5; Song, Hui-Zhu2; Liu, Jue1; Zhu, Wen-Hua5; Guo, Yi3; Jiao, Zheng1

2019-08-08

10.1111/nyas.14195

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES   影响因子和分区

0077-8923

1749-6632

Myasthenia gravis (MG) is an acquired autoimmune disease affecting the postsynaptic membrane of neuromuscular junctions and characterized by antibody-mediated T cell dependence and complement involvement. Cholinesterase inhibitors (e.g., pyridostigmine bromide), glucocorticoids, and azathioprine are currently recommended as first-line treatments for MG, though they have limitations, including potential toxicity and ineffectiveness in patients with refractory MG. In recent years, owing to an increasing understanding of MG pathogenesis the development and execution of clinical trials with novel biologics, including monoclonal antibodies (mAbs) that have demonstrated higher safety and more specificity, provide new opportunities for the treatment of MG. In this article, we review recent advances in MG pathogenesis and the mAbs that have been used for target-specific MG therapy.

myasthenia gravis immunopathology treatment strategy biological agents monoclonal antibody

SCI

英语

通讯

Medical Young Talents Program of Jiangsu Province[QNRC2016192]

Science & Technology - Other Topics

Multidisciplinary Sciences

WOS:000480897100001

WILEY

BIOLOGY & BIOCHEMISTRY;CLINICAL MEDICINE;MULTIDISCIPLINARY;MOLECULAR BIOLOGY & GENETICS

Web of Science

1.Fudan Univ, Huashan Hosp, Dept Clin Pharm, Shanghai 200040, Peoples R China
2.Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Pharm, Wuxi, Jiangsu, Peoples R China
3.Southern Univ Sci & Technol, Jinan Univ, Affiliated Hosp 1, Clin Med Coll 2,Shenzhen Peoples Hosp,Dept Neurol, Shenzhen 518020, Peoples R China
4.Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Neurol, Wuxi, Jiangsu, Peoples R China
5.Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China

Cai, Xiao-Jun,Li, Zai-Wang,Xi, Jian-Ying,et al. Myasthenia gravis and specific immunotherapy: monoclonal antibodies[J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,2019,1452(1):18-33.

Cai, Xiao-Jun.,Li, Zai-Wang.,Xi, Jian-Ying.,Song, Hui-Zhu.,Liu, Jue.,...&Jiao, Zheng.(2019).Myasthenia gravis and specific immunotherapy: monoclonal antibodies.ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,1452(1),18-33.

Cai, Xiao-Jun,et al."Myasthenia gravis and specific immunotherapy: monoclonal antibodies".ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 1452.1(2019):18-33.